Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by Mizuho in a research note issued on Sunday, Analyst Ratings.Net reports. They currently have a $130.00 price objective on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 35.29% from the stock’s current price. Several large investors have recently made changes […]
